Advertisement

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Peter Clark, MA, MD, FRCP: A Payer Perspective

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement

Apr

15

Today In Oncology

Large Language Models May Generate Concise, Coherent Pathology Summaries, Reducing Physician Burden

PSMA PET-CT Scan Reduces Need for Prostate Cancer Biopsies

Surgery Still Safe Beneficial For Many Octogenarian Patients With NSCLC

Prompting Strategies Improve Symptom Monitoring in Childhood Cancer Survivors

NCCN Names New Chief Scientific Officer

Advertisement

© 2026 HSP News Service, L.L.C.